Comparison
Creatine Monohydrate vs Semaglutide
Side-by-side of Creatine Monohydrate and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Creatine Monohydrate
Creatine monohydrate supplement guide: 3-5 g/day raises phosphocreatine stores, lifts anaerobic output 5-15%, supports lean mass and cognition under sleep loss.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Effects at a glance
Creatine Monohydrate
- •Increases anaerobic strength and power output by ~5 to 15% across multiple training studies
- •Adds ~1 to 2 kg of lean body mass over 4 to 12 weeks, partly intracellular water and partly true tissue gain
- •Improves 1-rep max on bench and squat by ~5 to 10% versus placebo in resistance-trained adults
- •Cognitive benefit appears mainly under sleep deprivation or high mental load, less so in well-rested individuals
- •Saturation reached in ~28 days at 3 to 5 g/day, or ~5 to 7 days with a 20 g/day loading phase
- •No evidence of renal harm in healthy adults across long-term studies; caution in pre-existing severe renal disease
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Side-by-side
| Attribute | Creatine Monohydrate | Semaglutide |
|---|---|---|
| Category | supplement | pharmaceutical |
| Also known as | creatine | Ozempic, Wegovy, Rybelsus |
| Half-life (hr) ↗ | 3 | 168 |
| Typical dose (mg) ↗ | 5000 | 2.4 |
| Dosing frequency | daily | weekly (SC); daily (oral Rybelsus) |
| Routes | oral | subcutaneous, oral |
| Onset (hr) | 168 | 24 |
| Peak (hr) | - | 72 |
| Molecular weight | 149.15 | 4113.58 |
| Molecular formula | C4H9N3O2 | - |
| Mechanism | Donates a phosphate group to ADP via creatine kinase, regenerating ATP during high-intensity, short-duration efforts. | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. |
| Legal status | Dietary supplement (most jurisdictions) | Prescription only (FDA-approved, EMA-approved) |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) |
| Pregnancy | Insufficient data | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 57-00-1 | 910463-68-2 |
| PubChem CID | 586 | 56843331 |
| Wikidata | Q408389 | Q27089394 |
Safety profile
Creatine Monohydrate
Common side effects
- water retention
- mild GI upset at loading doses
- weight gain (2 to 4 lb from intracellular water)
Contraindications
- severe renal impairment
Interactions
- caffeine (high-dose acute): mixed data on ergogenic interference; chronic use appears compatible(minor)
- nephrotoxic drugs (NSAIDs, cyclosporine): theoretical additive renal strain in at-risk patients(moderate)
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Creatine Monohydrate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Semaglutide is the right call when one of the conditionals below applies.
- → If your priority is strength or hypertrophy, pick Creatine Monohydrate.
- → If your priority is focus or working memory, pick Creatine Monohydrate.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
Edge case: If you want to avoid prescription-only, Creatine Monohydrate is the more accessible choice.
Default choice: Creatine Monohydrate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Semaglutide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Creatine Monohydrate and Semaglutide?
Creatine Monohydrate and Semaglutide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Creatine Monohydrate or Semaglutide?
Creatine Monohydrate half-life is 3 hours; Semaglutide half-life is 168 hours.
Can you stack Creatine Monohydrate with Semaglutide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper